NEW
YORK, June 2, 2023 /PRNewswire/
-- Jakubowitz Law announces that an investigation into
potential securities fraud allegations has commenced on behalf of
shareholders of Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
To be contacted by a member of our team, fill out the
form:
https://claimyourloss.com/securities/reata-class-action-loss-submission-form/?id=40181&from=4
Further details on the investigation: On May 10, 2023, Reata issued a press release
announcing its financial results for the first quarter of 2023.
Among other items, Reata announced its decision to discontinue
studies for its kidney disease candidate bardoxolone, which the
Company had previously advanced as one of its lead assets in
partnership with Blackstone Life Sciences and Kyoma
Kirin. On this news, Reata's stock price fell
$14.99 per share or 14.23%, to close
at $90.38 per share on May 10, 2023.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities fraud. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/reta-fraud-alert-jakubowitz-law-is-investigating-reata-pharmaceuticals-inc-in-connection-with-potential-violations-of-federal-securities-laws-301840863.html
SOURCE Jakubowitz Law